07103 Rec'd PCT/PTO 1 7 DEC 2004

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTTORNEY'S DOCKET NUMBER 67442-A-PCT-US

U.S. APPLICATION D. (J. kg/dwn s @ 37 CP 79 12)
Not Yet Assigned

CONCERMING A SUBMISSION ONDE	K 35 0.3.0. 37 1	Not yet Assigned							
	ATIONAL FILING DATE ly 3, 2003	PRIORITY DATE CLAIMED July 3, 2002							
TITLE OF INVENTION Secondary Amino Anilinic Piperidines A	As MCH1 Antagonists	And Uses Thereof							
APPLICANT(S) FOR DO/EO/US Mohammad R. Marzabadi, et al.									
Applicant herewith submits to the United States Designa	ited/Elected Office (DO/EC	D/US) the following items and other information:							
1. This is a FIRST submission of items concerning a sul	bmission under 35 U.S.C. 37	1.							
2. This is a SECOND or SUBSEQUENT submission of i	items concerning a submission	on under 35 U.S.C. 371.							
This is an express request to begin national examinat (5), (6), (9) and (21) indicated below.	tion procedures (35 U.S.C. 37	71(f)). The submission must include items							
4. The US has been elected (Article 31).									
5. A copy of the International Application as filed (35 to	J.S.C. 371(c)(2))	•							
a. a is attached hereto (required only if not co	mmunicated by the Internatio	nal Bureau).							
b.  has been communicated by the Internation	onal Bureau.								
c.  is not required, as the application was file	c. s not required, as the application was filed in the United States Receiving Office (RO/US).								
6. An English language translation of the Internationa	Application as filed (35 U.S.	C. 371(c)(2)).							
a. is attached hereto.									
b.  has been previously submitted under 35	U.S.C. 154(d)(4).								
7. Amendments to the claims of the International App	lication under PCT Article 19	(35 U.S.C. 371(c)(3))							
a. are attached hereto (required only if not	communicated by the Interna	ational Bureau).							
b. have been communicated by the Interna	ational Bureau.								
c. have not been made; however, the time	limit for making such amend	ments has NOT expired.							
d. Anave not been made and will not be ma	de.								
8. An English language translation of the amendmen	its to the claims under PCT A	rticle 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor(s) (35 U.S.C	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
An English language translation of the annexes of Article 36 (35 U.S.C. 371(c)(5)).	the International Preliminary	Examination Report under PCT							
Items 11 to 20 below concern document(s) or information	tion included:	·							
11. An Information Disclosure Statement under 37 CF	R 1.97 and 1.98.								
12. An assignment document for recording. A separate	e cover sheet in compliance v	with 37 CFR 3.28 and 3.31 is included.							
13. A preliminary amendment.									
14. An Application Data Sheet under 37 CFR 1.76.		*							
15. A substitute specification.		*							
16. A power of attorney and/or change of address letter	er.								
17. A computer-readable form of the sequence listing	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.								
18. A second copy of the published International Appli	A second copy of the published International Application under 35 U.S.C. 154(d)(4).								
19. A second copy of the English language translation	of the international application	on under 35 U.S.C. 154(d)(4). cation for PCT/US2003/21391; Certificate of Mailing by							
20. Other items or information: "Express Mail" (37 CFI	R 1.10), Express Mail Label N	o. ED 067094061 US and return postcard							

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## DT01 Rec'd PCT/PTC 1 7 DEC 2004

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
OF The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. U.S. APPLICATION O (I knowl) con 27 CER 4

Not Yet Assigned PCT/US2003/21391				ATTORNEY'S DOCKET NUMBER 67442-A-PCT-US				
	ing fees are submitted:					07442-X-FC1-C	<del></del>	
a) Basic national fee\$300.00						\$ 300		
b) Examination fee\$200.00					\$ 200			
✓ c) Search fee					s 500			
TOTAL OF ABOVE CALCULATIONS =					\$ 1000			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)			7			
128 <sup>- 100</sup> =	28 /50 =	1	1 \$250.00		\$ 250	Ţ <u></u>		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						\$		
CLAIMS	NUMBER FIL	ED	NUMBER EXTRA	F	ATE	\$	<u> </u>	
Total claims	40	- 20 =	20	× \$50.00		\$ 1000	<u> </u>	
Independent clain	ndent claims - 3 = x \$20		\$200.00	\$				
MULTIPLE DEPE	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00				\$360.00	\$	<del> </del>	
TOTAL OF ABOVE CALCULATIONS =						\$ 2250		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced \$ \$								
SUBTOTAL = \$ 2250								
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).								
on priority da	iic (57 Ct K 1.492(1)).		TOTAL	NATION	+			
TOTAL NATIONAL FEE = Fee for recording the enclosed assignment /37 CEB 4.24(b)). The						\$ 2250		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + 40						70		
TOTAL FEES ENCLOSED =					\$ 2290			
						Amount to be refunded:	\$	
						Amount to be charged:	\$	
a. A check	in the amount of \$ _ 229	90.00	to cover the abo	ve fees is	enclosed.			
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees.								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No503201 A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this formation on this formation on this formation on this formation.								
NOTE: Where an appropriate time limit under 37 CER 1.495 box not become 4.500 kg.								
Freedom to portain g status.								
SEND ALL CORRESPONDENCE TO:								
Synaptic Pharmaceutical Corporation Attention: Stephen G. Kalinchak, Legal  SIGNATURE SIGNATURE							77/40	
215 College Road							U	
Paramus, NJ 07652 Mary Catherine DiNunzio NAME								
37,306								
REGISTRATION NUMBER							1	

Docket No. 67442-A-PCT-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mohammad R. Marzabadi, et al. Group Art Unit: Not Yet Assigned

Application No.: Not Yet Assigned PCT/US2003/021391

Examiner: Not Yet Assigned

Filed: Herewith - December 17, 2004

July 3, 2003 (International Filing Date)

For: SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1

ANTAGONISTS AND USES THEREOF

Date: December 17, 2004

## CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 C.F.R. § 1.10)

Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

I hereby certify that the following correspondence:

Transmittal Letter to the United States Designated/Elected Office...(PTO-1390) (2 pages); Request (PCT/RO/101) (9 pgs); Specification (128 pgs); Fully Executed Assignment (3pgs); Recordation Form Cover Sheet (PTO-1595) (1 pg); Combined Declaration and Power of Attorney (4 pgs); Return Postcard and Check (\$2290)

is being deposited on <u>December 17, 2004</u> with the United States Postal Service for "Express Mail Post Office to Addressee" delivery under 37 C.F.R. § 1.10 in an envelope bearing sufficient postage and addressed to:

Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450.

Julianne Decker

(Typed Or Printed Name Of Person Mailing Correspondence)

(Signature Of Person Mailing Correspondence)

ED 067094061 US

("Express Mail" Mailing Label Number)